“Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s39. doi:10.25251/skin.4.supp.39.